Prior Antibodies to Infliximab or Adalimumab Are Related to Immunogenicity to Vedolizumab in Patients With Inflammatory Bowel Disease

被引：5
|
作者：
Papamichael, Konstantinos [1 ,7 ]
Vande Casteele, Niels [2 ]
Abraham, Bincy P. [3 ]
Ritter, Timothy [4 ]
Jain, Anjali [5 ]
Cheifetz, Adam S. [6 ]
机构：
[1] Beth Israel Deaconess Med Ctr, Ctr Inflammatory Bowel Dis, Boston, MA USA
[2] Univ Calif San Diego, Dept Med, La Jolla, CA USA
[3] Houston Methodist Hosp, Dept Med, Houston, TX USA
[4] GI Alliance Res, Southlake, TX USA
[5] Prometheus Labs, San Diego, CA USA
[6] Beth Israel Deaconess Med Ctr, Ctr Inflammatory Bowel Dis, Boston, MA USA
[7] Beth Israel Deaconess Med Ctr, Ctr Inflammatory Bowel Dis, 330 Brookline Ave, Boston, MA 02215 USA
来源：
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | 2023年 / 21卷 / 11期
关键词：
FAILURE;
D O I：
10.1016/j.cgh.2022.10.037
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：2978 / +
页数：5
相关论文
共 50 条
  • [41] Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients
    Van den Berghe, Nathalie
    Verstockt, Bram
    Tops, Sophie
    Ferrante, Marc
    Vermeire, Severine
    Gils, Ann
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (07) : 1175 - 1181
  • [42] THE CLINICAL AND FINANCIAL IMPACT OF MEASURING INFLIXIMAB LEVELS AND ANTIBODIES TO INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS
    O'Reilly, S.
    Keegan, D.
    Byrne, K.
    Sheridan, J.
    Mulcahy, H. E.
    Doherty, G. A.
    Cullen, G.
    GUT, 2017, 66 : A2 - A3
  • [43] Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients
    Van den Berghe, N.
    Verstockt, B.
    Tops, S.
    Ferrante, M.
    Vermeire, S.
    Gils, A.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S351 - S351
  • [44] Is Vedolizumab Truly Gut Selective? It May Not Affect the Immunogenicity of Vaccines in Patients With Inflammatory Bowel Disease
    Lee, Alexander S.
    Caldera, Freddy
    CROHNS & COLITIS 360, 2020, 2 (04)
  • [45] Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease
    Mayte Gil-Candel
    Juan José Gascón-Cánovas
    Elena Urbieta-Sanz
    Lorena Rentero-Redondo
    María Onteniente-Candela
    Carles Iniesta-Navalón
    International Journal of Clinical Pharmacy, 2020, 42 : 500 - 507
  • [46] Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease
    Gil-Candel, Mayte
    Gascon-Canovas, Juan Jose
    Urbieta-Sanz, Elena
    Rentero-Redondo, Lorena
    Onteniente-Candela, Maria
    Iniesta-Navalon, Carles
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2020, 42 (02) : 500 - 507
  • [47] Uptake of drug monitoring of infliximab and adalimumab in inflammatory bowel disease in Australia
    Janko, N.
    Little, R. D.
    Sparrow, M. P.
    Gibson, P. R.
    Ward, M. G.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 136 - 137
  • [48] Comparison of Infliximab Immunogenicity in Inflammatory Arthritis Versus Inflammatory Bowel Disease Patients in Routine Clinical Practice
    Guirgis, Marianne
    Jeanfavre, Melanie Favre Dit
    Benaim, Charles
    Perreau, Matthieu
    Michetti, Pierre
    Maillard, Michel
    Zufferey, Pascal
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [49] Efficacy of vedolizumab in patients with inflammatory bowel disease and failure of anti-TNF-antibodies
    Hoog, C.
    Eberhardson, M.
    Almer, S.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S310 - S310
  • [50] Influence of initial albumin levels on infliximab and adalimumab trough levels in inflammatory bowel disease patients
    Gonzalez-Lopez, J.
    Llamas, C.
    Giraldez-Montero, J. M.
    Ferreiro, R.
    Baston, I.
    Lamas, M. J.
    Dominguez-Munoz, J. E.
    Barreiro-de Acosta, M.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S248 - S249
12345